Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
- Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase 1 (SOD1) mutation
- Late breaking interim data to be presented at the American Academy of Neurology Annual Meeting (AAN) show a statistically significant reduction in SOD1 protein levels and a numerical trend towards slowing of clinical decline in SOD1-ALS patients treated with tofersen
- Biogen recently initiated VALOR, a phase 3 clinical trial to confirm the efficacy and safety of tofersen in SOD1-ALS patients
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today interim results of a phase 1/2 study of tofersen, an antisense oligonucleotide (ASO) being studied for the potential treatment of amyotrophic lateral sclerosis (ALS) in adults with a confirmed superoxide dismutase 1 (SOD1) mutation. The data will be presented at the American Academy of Neurology Annual Meeting (AAN) in Philadelphia, PA (May 4-10, 2019).
“The interim results of this study, which achieved proof-of-biology and proof-of-concept, support the initiation of a phase 3 clinical trial to confirm the efficacy and safety of tofersen in SOD1-ALS patients and further demonstrate the potential of ASOs to target the genetic driver of disease,” said Michael Ehlers, M.D., Ph.D., executive vice president, research and development at Biogen. “We are committed to bringing a potential breakthrough therapy to patients with ALS and we are expediting our efforts with the aim of addressing this urgent unmet need.”
The Phase 1/2 study of tofersen in SOD1-ALS is a randomized, placebo-controlled, single- and multiple-ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy endpoints of tofersen in 70 patients with ALS. In the multiple ascending dose portion of the study, 50 participants with SOD1 mutations were randomized to receive tofersen (20 mg, 40 mg, 60 mg, or 100 mg) or placebo for 12 weeks.
In the interim analysis, treatment with tofersen 100 mg (n=10) over a three-month period resulted in a statistically significant lowering of SOD1 protein levels in the cerebrospinal fluid (p=0.002) and a numerical trend towards slowing of clinical decline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), slow vital capacity and muscle strength compared to placebo (n=12). Specifically, the mean change in ALSFRS-R score from baseline to Day 85 was -1.1 in the tofersen 100 mg group compared to -5.3 in the placebo group, on a 48-point scale. Across clinical measures, separation from the placebo group was most apparent in patients with fast progressing disease. The safety and tolerability profile in this analysis supports continued development of tofersen in ALS. The data will be presented by study co-principal investigator Timothy M. Miller, M.D., Ph.D., of the Washington University School of Medicine in St. Louis, MO on May 7, 2019 at 11:45 a.m. ET as a late breaking oral presentation.
“ALS is a devastating disease and there are currently no therapeutic options that reliably slow or halt its rapid progression,” said Merit Cudkowicz, M.D., co-principal investigator and the director of the Healey Center at Massachusetts General Hospital. “We are encouraged by the positive results of this phase 1/2 study of tofersen in patients with SOD1-ALS and are excited to advance this clinical program to a phase 3 trial to further investigate its therapeutic potential.”
In March 2019 the first patient was dosed in the Phase 3 VALOR study of tofersen in adults with ALS with a confirmed SOD1 mutation. The VALOR study aims to assess the efficacy and safety of tofersen versus placebo. The primary endpoint of this study is an analysis based on the ALSFRS-R score, which is a validated rating instrument that monitors the progression of disability in patients with ALS. Biogen is collaborating with regulators to further define the scope of the clinical data package required to support the registration of tofersen.
ALS is a rare and fatal neurodegenerative disease characterized by motor neuron loss in the brain and spinal cord that is responsible for controlling voluntary muscle movement. Symptoms may vary depending on the location of the motor neuron failure and may include limb weakness, difficulty breathing and trouble speaking and swallowing. There is a growing body of evidence that mutations within multiple genes are believed to cause ALS. ALS with SOD1 mutations is a rare subtype of familial ALS and accounts for approximately two percent of all ALS cases.
Tofersen is an antisense oligonucleotide (ASO) being developed for the treatment of ALS with SOD1 mutations. Tofersen binds to SOD1 mRNA, allowing for its degradation by RNase-H and reduction of SOD1 protein production. This is thought to decrease the toxicity of mutant SOD1 and potentially provide therapeutic benefit through improved survival and function to people with ALS with SOD1 mutations. Tofersen demonstrated proof-of-biology and proof-of-concept in a Phase 1/2 study. Biogen licensed tofersen from Ionis Pharmaceuticals, Inc. under a collaborative development and license agreement.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor Statement
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about results from the Phase 1/2 study of tofersen; the potential clinical effects of tofersen; the potential benefits, safety and efficacy of tofersen; the clinical development program for tofersen; the potential of our commercial business and pipeline programs, including tofersen; the anticipated benefits and potential of our collaboration arrangements with Ionis; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, uncertainty of success in the development and potential commercialization of tofersen; the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected; unexpected concerns may arise from additional data, analysis or results obtained during our clinical trials; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, including tofersen; the occurrence of adverse safety events; the risks of other unexpected hurdles, costs or delays; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release.
We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
+1 617 679 4945
+1 781 464 4471
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
SDRL – Seadrill Limited Announces Contract Award for the West Gemini17.7.2019 22:35:00 CEST | Press release
Hamilton, Bermuda, July 17, 2019 - Seadrill Limited ("Seadrill" or "the Company") has secured a nine well contract with three options, each for two wells, for the West Gemini in West Africa. Total contract value for the firm portion of the contract is expected to be approximately $84 million with commencement expected in early Q4 2019 and running through Q4 2020. FORWARD LOOKING STATEMENTS This news release includes forward looking statements. Such statements are generally not historical in nature, and specifically include statements about the Company's plans, strategies, business prospects, changes and trends in its business, the markets in which it operates and its restructuring efforts. These statements are made based upon management's current plans, expectations, assumptions and beliefs concerning future events impacting the Company and therefore involve a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or imp
GrandVision confirms HAL and EssilorLuxotica are engaged in discussions on a possible sale of controlling interest of HAL in GrandVision17.7.2019 18:45:00 CEST | Press release
Schiphol, The Netherlands - 17 July 2019. GrandVision NV (Euronext: GVNV) confirms that it has been approached by EssilorLuxottica SA (Euronext: EL) and HAL Holding NV (Euronext: HAL) in connection with a possible sale of HAL’s 76.72% ownership interest in GrandVision to EssilorLuxottica at an envisaged purchase price per share of approximately EUR28.00. At this stage it is uncertain whether an agreement between EssilorLuxottica and HAL will be reached. While a transaction would be between HAL and EssilorLuxottica, GrandVision’s support has been requested. Completion of a sale of HAL’s ownership interest in GrandVision would be subject to customary conditions including approval from relevant regulatory authorities in various jurisdictions, which may take between 12 and 24 months. Following completion of the transaction between HAL and EssilorLuxottica, EssilorLuxottica will make a (mandatory) public offer for all shares in GrandVision. Further announcements will be made if and when req
Solutions 30 : 79.8% revenue growth in the first half of 201917.7.2019 18:00:00 CEST | Press release
79.8% revenue growth in the first half of 2019 France: revenue up 74.4% Other countries: revenue up 90.3% Reliable, cash-generating model Solutions 30 SE, the European leader in solutions for new technologies, today disclosed its revenue for the first half of 2019 . In millions of euros (Unaudited figures) HY Q2 2019 2018 % change 2019 2018 % change Total 317.8 176.7 +79.8% 157.4 91.5 +72.1% From France 202.8 116.3 +74.4% 101.5 59.5 +70.6% From other countries 115.0 60.4 +90.3% 55.9 32.0 +74.7% Sustained growth trend continues Solutions 30 maintains its high growth trajectory, disclosing revenues of €317.8 million for the first half of 2019, a 79.8% increase (36.9% of which was organic growth1). For the 2nd quarter alone, revenue increased by 72.1%, reaching €157.4 million. Organic growth represented 32.3%. The group continues to demonstrate the relevance of its positioning and strategy in markets driven by the economy’s digital transformation and major technology groups’ outsourcing o
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban17.7.2019 18:00:00 CEST | Press release
Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA - July 17, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today hosted a key opinion leader (KOL) meeting in New York City on in-vitro fertilization (IVF). At the event, three KOLs in women’s reproductive health along with company executives discussed trends in IVF, including current practice trends toward Day 5 embryo transfer, and the merits of single-embryo transfer (SET) vs. double embryo transfer (DET). Further, event participants discussed the potential clinical importance of nolasiban, ObsEva’s oral oxytocin receptor antagonist, to significantly improve the live birth rate (LBR) resulting from ET, and address the high physical, emotional and financial pain associated with fa
Bizagi goes from Stealth to Hyper Growth Delivering Digital Transformation for World Leading Brands17.7.2019 18:00:00 CEST | Press release
From Adidas and Audi to Ikea and the U.S. government, Bizagi’s unique Intelligent Process Automation helping organizations harness the power of RPA and AI to speed transformation SANTA CLARA, Calif., July 17, 2019 (GLOBE NEWSWIRE) -- Bizagi, the world’s leading Intelligent Process Automation platform provider, today announced significant growth in the U.S. and abroad driven by its success enabling digital transformation for world leading brands such as DHL, Gap, Citizens Bank, AON and numerous U.S. government agencies including the Departments of Agriculture, Defense, Energy, HHS, Homeland Security and many others. Bizagi’s growth is based on enterprise adoption of its unique Intelligent Process Automation, enabling companies to better leverage digital and robotic processes, along with artificial intelligence, to improve customer interaction, speed operations and build revenue. This news follows the company’s recognition last month as a leader in The Forrester Wave™: Software for Digit
EnBW International Finance B.V.: Half-yearly report17.7.2019 17:00:00 CEST | Press release
EnBW International Finance B.V.: Half-yearly report 2019 In accordance with the Transparency Directive (Directive 2004/109/EC), as amended by the Transparency Directive Amending Directive (Directive 2013/50/EU), and following the choice of EnBW International Finance B.V. for The Netherlands as Home Member State, EnBW International Finance B.V. hereby informs that the half-year financial reports for the period 1 January 2019 till 30 June 2019 have been filed on 17 July 2019 with the Autoriteit Financiële Markten (AFM) in The Netherlands and are available on the internet site: https://www.enbw.com/unternehmen/investoren/news-und-publikationen/publikationen/